We reiterate our BUY recommendation, valuing the stock at 2.8x Sep'25E ABV (vs current valuation of 2.7x Sep'25E ABV), its core book and a subsidiary value of Rs 185/share, to arrive at a target price of Rs 1,325/share. The TP implies an upside sof 20% from the CMP.